SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million , before deducting

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida .

Blinded, randomized, placebo-controlled, 40-week extension trial, TRCA-301E, met its primary and all secondary endpoints, supporting the long-term safety and efficacy profile of TRC101 Patients treated with TRC101 showed a significant reduction in all-cause mortality and progression of CKD (defined

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

Webcast Today at 8:00 am Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 27, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report results from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning at 7:15 am Eastern Time . Tricida will host a conference call and webcast at 8:00 am Eastern

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 11, 2019-- Tricida, Inc., (Nasdaq: TCDA) a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 7, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019 .

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, March 12, 2019 at 8:20 am PT / 11:20 am ET . Geoff Parker , Tricida’s Chief Financial Officer,